中国人群早孕期子痫前期筛查策略的前瞻性评估及临床适用性
该研究在中国大陆13家医院前瞻性纳入10 899名单胎孕妇,采用FMF竞争风险模型联合MAP、UtA-PI和PAPP-A筛查早产型子痫前期,在10%、15%、20%假阳性率下检出率分别为65.0%、72.7%和76.1%,且筛查阳性者其他胎盘相关不良结局风险增高。
要点
- FMF竞争风险模型在中国大陆人群筛查早产型PE有效,10%假阳性率下检出率65.0%。
- 用PlGF替代PAPP-A或添加PlGF未改善筛查性能。
- 早产型PE筛查阳性者约30%发生至少一种胎盘相关不良结局。
核心结论
- FMF竞争风险模型在中国大陆人群筛查早产型PE有效。
- 早产型PE筛查阳性女性其他胎盘相关妊娠并发症风险增高。
- 用PlGF替代PAPP-A或添加PlGF未改善筛查性能。
研究设计与样本
- 前瞻性多中心观察性队列研究,纳入10 899名单胎孕妇,来自中国大陆7个城市13家医院。
- 纳入时间为2017年12月1日至2019年12月30日。
- 于孕11+0至13+6周测量MAP、UtA-PI及血清PlGF和PAPP-A,并转换为中国参考范围的中位数倍数。
- 采用FMF算法计算早产型PE个体化风险,先验风险基于母亲人口学特征和产科病史。
主要发现
- 共识别312例发生PE的妊娠,其中117例为早产型PE(<37周)。
- 386例妊娠并发严重复合胎盘相关不良结局,包括早产型PE、146例严重SGA(出生体重<第3百分位)、61例胎盘早剥和109例早期早产(<34周)。
- 含MAP、UtA-PI和PAPP-A的三联标志物模型在固定假阳性率10%、15%和20%时,对早产型PE的检出率分别为65.0%、72.7%和76.1%。
- 同一模型对严重复合胎盘相关不良结局的检出率分别为34.7%、41.7%和46.4%。
- 在固定5%假阳性率下筛查早产型PE阳性的女性中,估计30%发生至少一种胎盘相关不良妊娠结局,包括PE、胎盘早剥、SGA(出生体重<第10百分位)和<37周早产。
关键数值与推荐
- 早产型PE定义为<37周妊娠诊断的PE。
- 严重SGA定义为出生体重<第3百分位。
- 早期早产定义为<34周妊娠分娩。
- 固定假阳性率10%、15%、20%下早产型PE检出率分别为65.0%、72.7%、76.1%。
- 固定5%假阳性率下早产型PE筛查阳性者中约30%发生至少一种胎盘相关不良结局。
临床怎么用
- 可在早孕期(11+0至13+6周)采用FMF竞争风险模型联合MAP、UtA-PI和PAPP-A筛查早产型PE。
- 筛查阳性者除早产型PE外,还应关注其他胎盘相关不良结局(如胎盘早剥、SGA、早产)的风险。
- PlGF替代PAPP-A或添加PlGF未显示额外获益,可依据资源选择三联标志物方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate, in a Chinese population, the performance of a screening strategy for preterm pre-eclampsia (PE) using The Fetal Medicine Foundation (FMF)'s competing-risks model and to explore its clinical applicability in mainland China. METHODS: This was a prospective, multicenter, observational cohort study including 10 899 women with singleton pregnancy who sought prenatal care at one of 13 hospitals, located in seven cities in mainland China, between 1 December 2017 and 30 December 2019. Mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and maternal serum levels of placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A) at 11 + 0 to 13 + 6 weeks' gestation were measured and converted into multiples of the median using Chinese reference ranges. Individualized risk for preterm PE was calculated using the FMF algorithm. Prior risk was calculated based on maternal demographic characteristics and obstetric history. We evaluated the efficiency of the screening strategy using various combinations of biomarkers and analyzed its predictive performance for a composite of placenta-associated adverse pregnancy outcomes, including PE, placental abruption, small-for-gestational age (SGA) and preterm birth, at fixed false-positive rates for preterm PE. RESULTS: We identified 312 pregnancies that developed PE, of which 117 cases were diagnosed as preterm PE (< 37 weeks' gestation). There were 386 pregnancies complicated by severe composite placenta-associated adverse outcome, including preterm PE, 146 cases of severe SGA (birth weight < 3rd percentile) neonate, 61 cases with placental abruption and 109 cases of early preterm birth < 34 gestational weeks. The triple-marker model containing biomarkers MAP, UtA-PI and PAPP-A achieved, at fixed false-positive rates of 10%, 15% and 20%, detection rates for preterm PE of 65.0%, 72.7% and 76.1%, respectively, and detection rates for severe composite placenta-associated adverse outcome of 34.7%, 41.7% and 46.4%, respectively. Replacing PAPP-A with PlGF or adding PlGF to the model did not improve the performance. Of women screening positive for preterm PE at a fixed 5% false-positive rate, an estimated 30% developed at least one placenta-associated adverse pregnancy outcome, including PE, placental abruption, SGA (birth weight < 10th percentile) and preterm birth < 37 weeks. CONCLUSIONS: The FMF competing-risks model for preterm PE was found to be effective in screening a mainland Chinese population. Women who screened positive for preterm PE had increased risk for other placenta-associated pregnancy complications. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Hu J, Gao J, Liu J, et al. Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China. Ultrasound Obstet Gynecol. 2021. PMID: 33817865. doi:10.1002/uog.23645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。